Kintara Therapeutics, Inc. (NASDAQ:KTRA) Expected to Post Earnings of -$0.11 Per Share

Wall Street brokerages expect Kintara Therapeutics, Inc. (NASDAQ:KTRAGet Rating) to announce ($0.11) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Kintara Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.06). Kintara Therapeutics reported earnings per share of ($0.13) during the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Kintara Therapeutics will report full year earnings of ($0.59) per share for the current fiscal year. For the next year, analysts anticipate that the company will post earnings of ($0.55) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Kintara Therapeutics.

Kintara Therapeutics (NASDAQ:KTRAGet Rating) last released its quarterly earnings data on Friday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04.

Several brokerages have weighed in on KTRA. HC Wainwright dropped their target price on Kintara Therapeutics from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, January 20th. Dawson James downgraded Kintara Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday.

KTRA stock remained flat at $$0.16 during trading hours on Tuesday. The company had a trading volume of 1,586,348 shares, compared to its average volume of 1,806,261. Kintara Therapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $2.85. The firm has a market capitalization of $7.95 million, a P/E ratio of -0.27 and a beta of 1.69. The firm has a 50 day moving average of $0.32 and a 200-day moving average of $0.48.

Several large investors have recently bought and sold shares of KTRA. Geode Capital Management LLC lifted its holdings in Kintara Therapeutics by 5.1% during the 3rd quarter. Geode Capital Management LLC now owns 292,064 shares of the company’s stock worth $251,000 after purchasing an additional 14,097 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Kintara Therapeutics in the 3rd quarter valued at about $47,000. Renaissance Technologies LLC bought a new stake in shares of Kintara Therapeutics in the 4th quarter valued at about $104,000. Citadel Advisors LLC bought a new stake in shares of Kintara Therapeutics in the 4th quarter valued at about $127,000. Finally, Virtu Financial LLC lifted its stake in shares of Kintara Therapeutics by 371.4% in the 4th quarter. Virtu Financial LLC now owns 64,913 shares of the company’s stock valued at $33,000 after purchasing an additional 51,144 shares during the period. Institutional investors and hedge funds own 10.37% of the company’s stock.

Kintara Therapeutics Company Profile (Get Rating)

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

See Also

Get a free copy of the Zacks research report on Kintara Therapeutics (KTRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.